phase study investigating safety pharmacokinetics highly bioavailable curcumin theracurmin cancer patients pubmed ncbi abstract background growing number preclinical studies demonstrated curcumin promising anticancer drug poor bioavailability major obstacle clinical application overcome problem developed form curcumin theracurmin reported high plasma curcumin levels safely achieved single administration theracurmin healthy volunteers study aimed evaluate safety repetitive administration theracurmin cancer patients methods pancreatic biliary tract cancer patients failed standard chemotherapy eligible study based previous pharmacokinetic study selected theracurmin num mg curcumin level num starting dose dose safely escalated level num contained num mg curcumin theracurmin orally administered day standard gemcitabine-based chemotherapy addition safety pharmacokinetics data nf activity cytokine levels efficacy quality-of-life score evaluated results ten patients assigned level num level num peak plasma curcumin levels median theracurmin administration num ng/ml range num num ng/ml level num num ng/ml range num num ng/ml level num unexpected adverse events observed num patients safely continued theracurmin administration num months conclusions repetitive systemic exposure high concentrations curcumin achieved theracurmin increase incidence adverse events cancer patients receiving gemcitabine-based chemotherapy 
